Tilson Financial Group Inc. Invests $258,000 in Johnson & Johnson (NYSE:JNJ)

Tilson Financial Group Inc. bought a new stake in Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,593 shares of the company’s stock, valued at approximately $258,000.

Several other hedge funds have also bought and sold shares of JNJ. Innealta Capital LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $27,000. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth approximately $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares in the last quarter. Morton Brown Family Wealth LLC grew its position in Johnson & Johnson by 400.0% during the third quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company’s stock valued at $41,000 after acquiring an additional 200 shares during the last quarter. Finally, MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth approximately $43,000. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. The Goldman Sachs Group lowered their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Citigroup increased their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Finally, Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $159.86 on Friday. The business has a 50 day moving average of $163.39 and a 200 day moving average of $155.35. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The company has a market cap of $384.88 billion, a PE ratio of 23.13, a P/E/G ratio of 2.85 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.66 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.10%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.